Program
ficerafusp alfa
Also written as “Ficerafusp alfa” and “BCA101”.
Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by Bicara Therapeutics.
Furthest: phase 3, since Jan 10, 20253 company-led studies, 3 open or runningNext primary completion: Oct 31, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bicara Therapeutics | 33 open or running | phase 3since Jan 10, 2025 | Jun 10, 2020 | Oct 31, 2027phase 1 · NCT04429542 |
Also a collaborator on its studies: Merck.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 10, 2020First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT04429542 · 473 planned · United States, Australia, Canada
- Jan 10, 2025Phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06788990 · 650 planned · United States, Argentina, Australia and more
- Aug 18, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07807163 · 160 planned · United States
Ahead
- Oct 31, 2027Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT04429542
- Mar 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07807163
- Apr 2028Primary completion: phase 3 study in Squamous Cell Carcinoma of Head and NeckNCT06788990
TargetBeta
“A bifunctional monoclonal antibody targeting both the receptor tyrosine kinase epidermal growth factor receptor (EGFR) and the pro-inflammatory cytokine human transforming growth factor beta (TGF-beta; TGFb), ”NCIt, by rule
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07807163Squamous Cell Carcinoma of Head and Neck · United States | 2 | Recruiting | Mar 2028 | 160 |
| NCT06788990Squamous Cell Carcinoma of Head and Neck · United States, Argentina, Australia and more | 3 | Recruiting | Apr 2028 | 650 |
| NCT04429542Squamous Cell Carcinoma of Head and Neck · United States, Australia, Canada | 1 | Recruiting | Oct 31, 2027 | 473 |
How it is read
Names in the registry
- “Ficerafusp alfa”, 2 entries
- “BCA101”, 1 entry
Conditions, from the studies’ own filings
- Squamous Cell Carcinoma of Head and Neck, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.